...
首页> 外文期刊>BioMetals: An International Journal on the Role of Metal Ions in Biology, Biochemistry and Medicine >Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease
【24h】

Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease

机译:铁代谢被扰乱,抗铜治疗改善但不正常化威尔逊疾病中的铁代谢

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Wilson's disease (WD) is a rare hereditary disorder of copper metabolism. Some data suggest that iron metabolism is disturbed in WD and this may affect the course of the disease. The current study aimed to determine whether anti-copper treatment could affect iron metabolism in WD. One hundred thirty-eight WD patients and 102 controls were examined. Serum ceruloplasmin and copper were measured by colorimetric enzyme assay or atomic adsorption spectroscopy, respectively. Routine and non-routine parameters of iron metabolism were measured by standard laboratory methods or enzyme immunoassay, respectively. WD patients, both newly diagnosed and treated, had less serum copper and ceruloplasmin than controls (90.0, 63.0, 22.0 mg/dL, respectively, p < 0.001); in the treated patients blood copper and ceruloplasmin were lower than in untreated patients (p < 0.001). Untreated patients (n = 39) had a higher median blood iron (126.0 vs 103.5 ug/dL, p < 0.05), ferritin (158.9 vs 47.5 ng/mL, p < 0.001), hepcidin (32, 6 vs 12.1 ng/mL, p < 0.001) and sTfR (0.8 vs. 0.7 ug/mL, p < 0.001) and lower blood transferrin (2.4 vs. 2.7 g/L, p < 0.001), TIBC (303.0 vs 338.0 ug/dL, p < 0.001), hemoglobin (13.1 vs 13.9 g/dL, p < 0.01) and RBC (4.3 vs. 4.6, p < 0.002) than controls. Treated patients (n = 99) had a significantly lower median iron (88.0 vs. 126.0 ug/dL, p < 0.001), ferritin (77.0 vs. 158.9 ng/mL, p < 0.005) and hepcidin (16.7 vs. 32.6 ng/mL, p < 001) and higher transferrin (2.8 vs. 2.4 g/L, p < 0.005), TIBC (336.0 vs 303.0 ug/dL, p < 0.001), RBC (4.8 vs. 4.3 M/L, p < 0.001) and hemoglobin (14.4 vs. 13.1 g/dL, p < 0.001) than untreated; the median iron (p < 0.005) was lower, and ferritin (p < 0.005), RBC (p < 0.005) and hepcidin (p < 0.002) were higher in them than in the control group. Changes in copper metabolism are accompanied by changes in iron metabolism in WD. Anti-copper treatment improves but does not normalize iron metabolism.
机译:威尔逊的疾病(WD)是一种难以遗传的铜代谢疾病。一些数据表明铁代谢在WD中受到干扰,这可能会影响疾病的过程。目前的研究旨在确定抗铜治疗是否可能影响WD中的铁代谢。检查了一百三十八名WD患者和102例对照。通过比色酶测定或原子吸附光谱法测量血清刺激纤维蛋白和铜。通过标准实验室方法或酶免疫测定法测量铁代谢的常规和非常规参数。 WD患者新诊断和治疗,血清铜和刺肌多于对照(90.0,63.0,22.0mg / dl,分别为P <0.001);在治疗的患者中,血铜和帽子均低于未处理的患者(P <0.001)。未经处理的患者(n = 39)具有更高的中位数血氧(126.0 Vs 103.5 UG / DL,P <0.05),铁蛋白(158.9 Vs 47.5 ng / ml,P <0.001),肝素(32,6 Vs 12.1ng / ml ,P <0.001)和STFR(0.8与0.7 Ug / mL,P <0.001)和低血液转移素(2.4对2.7g / L,P <0.001),TIBC(303.0 Vs 338.0 UG / DL,P <0.001 ),血红蛋白(13.1 vs13.9g / dl,p <0.01)和RBC(4.3与4.6,P <0.002)。治疗的患者(n = 99)具有显着低位的中生铁(88.0与126.0 ug / dl,p <0.001),铁蛋白(77.0与158.9 ng / ml,p <0.005)和肝素(16.7与32.6 ng / ML,P <001)和更高的转移素(2.8对2.4g / L,P <0.005),TIBC(336.0 Vs 303.0 UG / DL,P <0.001),RBC(4.8与4.3 m / L,P <0.001 )和血红蛋白(14.4 vs.13.1g / dl,p <0.001)不得治疗;中位数铁(P <0.005)较低,并且铁蛋白(P <0.005),RBC(P <0.005)和肝素(P <0.002)较高,而不是对照组。铜代谢的变化伴有WD中铁代谢的变化。抗铜治疗改善但不正常化铁代谢。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号